- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT06888687
Confronto del supporto dietetico con e senza monitoraggio continuo del glucosio in soggetti con diabete di tipo 2. (CARE-T2D)
Dietetica remota e health remota di monitoraggio del glucosio continuo per potenziare le persone con diabete di tipo 2
A parallel, single-blinded, randomised clinical trial conducted remotely across Australia from the Mary MacKillop Institute for Health Research (MMIHR, Australian Catholic University) for individuals with type 2 diabetes, by researchers from Australian Catholic University, University of Adelaide, University of Queensland, University of Wollongong, Monash University, Monash Partners, Deakin University, La Trobe University and Melbourne University.
Panoramica dello studio
Stato
Intervento / Trattamento
Descrizione dettagliata
In a parallel groups design, a total of 156 individuals will be recruited. After baseline pathology (HbA1c), blinded (Libre Pro iQ) continuous glucose monitoring (CGM) data and questionnaires (via REDCap) have been collected, participants will be randomised into one of two groups (DIET, dietetic support only; CGMD, CGM plus dietetic support). All participants will receive four (4) dietetic consults via telehealth at weeks 2, 6, 10 and 16, the content of which will be related to the randomised condition. Measurements will be repeated at 3 and 6 months from baseline to assess the changes in primary and secondary outcomes.
Tipo di studio
Iscrizione (Effettivo)
Fase
- Non applicabile
Contatti e Sedi
Luoghi di studio
-
-
Victoria
-
Melbourne, Victoria, Australia, 3065
- Australian Catholic University
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- Aged 18+ years
- Reside anywhere in Australia and have a postal address
- Confirmed T2D diagnosis by a GP/endocrinologist
- Current HbA1c of ≥7.0%
- Have a smartphone and able to independently use it
Exclusion Criteria:
- Under the age of 18 years
- Use of insulin therapy (within the last three months) or medications which interfere with blood glucose levels (i.e. steroids)
- Use of CGM within the last six months
- Eating Disorder Examination Questionnaire (EDE-Q) global score >2.8 OR global score > or equal to 1.52, with sum of Q14-18 > or equal to 4
- Currently having ongoing consultations with an APD or have had a consult with an APD (within last three months)
- Not weight stable (>5 kg change over last three months)
- Severe hypoglycaemic event (i.e. requiring assistance) within last six months
- Change of antihyperglcyaemic medications within last three months
- Women who are pregnant or breastfeeding (within 24 weeks)
- History of psychotic disorder, or current diagnosis of other major psychiatric illness (e.g. mood disorder, eating disorder, substance use disorder)
- History of blood disorders (including but, not limited to, anemia and thalassemia) that impact the primary outcome (HbA1c)
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Doppio
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Comparatore attivo: Dietetic support only
This group is designed to act as a comparator using 'standard care' in dietetics practice. Dietary advice provided to this participant group will be performed by Accredited Practicing Dietitians (APDs) in line with evidence-based guidelines, specifically the T2DM best-practice guidelines plus Australian Dietary Guidelines (i.e. Australian Guide to Healthy Eating) to improve diet quality, and strategies to promote adherence. |
Dietary advice will be provided by Accredited Practicing Dietitians (APDs) in line with evidence-based guidelines, specifically the T2DM best-practice guidelines plus Australian Dietary Guidelines (i.e. Australian Guide to Healthy Eating) to improve diet quality, and strategies to promote adherence. |
|
Sperimentale: CGM plus dietetic support
The CGM plus dietetic support group will be provided 'standard care' dietetic support alongside the use, and interpretation of, the CGM data collected to assist in the understanding of dietary modifications on glucose management. As per the DIET group, dietary advice provided to this participant group will be performed by Accredited Practicing Dietitians (APDs) in line with evidence-based guidelines, specifically the T2DM best-practice guidelines plus Australian Dietary Guidelines (i.e. Australian Guide to Healthy Eating) to improve diet quality, and strategies to promote adherence. The CGM data collected via LibreLink will be used by both the participant and the dietitian to inform dietary modifications. |
Dietary advice will be provided by Accredited Practicing Dietitians (APDs) in line with evidence-based guidelines, specifically the T2DM best-practice guidelines plus Australian Dietary Guidelines (i.e. Australian Guide to Healthy Eating) to improve diet quality, and strategies to promote adherence. Abbott FreeStyle Libre 2+ CGM sensors will be used to provide feedback on interstitial glucose concentrations over 15 day periods per sensor. Nine sensors will be provided for the 6-month period, for 3 months of continuous use and 3 months of intermittent (2 weeks on - 2 weeks off) use. |
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
HbA1c
Lasso di tempo: baseline, 6 months
|
Glycated haemoglobin concentration |
baseline, 6 months
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
HbA1c
Lasso di tempo: 3 months
|
Glycated haemoglobin concentration |
3 months
|
|
24 h assessment of glycaemia
Lasso di tempo: baseline, 6 months
|
24 h glucose measures assessed by blinded CGM (including, but not limited to, time in range, CV) |
baseline, 6 months
|
Altre misure di risultato
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
CGM application and use
Lasso di tempo: From 0 to 26 weeks, per 2 week period of sensor use
|
number of days of CGM use and interaction with viewing CGM data (via LibreLink); CGMD group ony |
From 0 to 26 weeks, per 2 week period of sensor use
|
|
Per protocol analysis
Lasso di tempo: 6 months
|
Primary analysis of the primary outcome (0-6 months HbA1c) is going to be intention to treat. Therefore, secondary analysis of all other variables will be a per-protocol (PP) analysis. Inclusion in PP analysis will be defined by: 1. Attendance at ≥3 dietetic consults, within ±10 days of the designated 2-, 6-, 10- and 16-week time points. |
6 months
|
|
Dietary intake
Lasso di tempo: baseline, 3 months, 6 months
|
energy and macronutrient composition calculated from food records |
baseline, 3 months, 6 months
|
|
Fasting blood glucose
Lasso di tempo: baseline, 3 months, 6 months
|
fasting blood glucose concentrations |
baseline, 3 months, 6 months
|
|
Adherence
Lasso di tempo: baseline, 4 weeks, 8 weeks, 12 weeks, 16 weeks, 18 weeks, 20 weeks, 26 weeks
|
measures of adherence assessed by self-report (questionnaire) |
baseline, 4 weeks, 8 weeks, 12 weeks, 16 weeks, 18 weeks, 20 weeks, 26 weeks
|
|
hs-CRP
Lasso di tempo: baseline, 3 months, 6 months
|
fasting high sensitive C-Peptide concentrations |
baseline, 3 months, 6 months
|
|
Fasting cholesterol
Lasso di tempo: baseline, 3 months, 6 months
|
Fasting cholesterol concentrations (total, HDL and LDL) |
baseline, 3 months, 6 months
|
|
Fasting lipid concentration
Lasso di tempo: baseline, 3 months, 6 months
|
fasting triglyceride concentrations |
baseline, 3 months, 6 months
|
|
Medication effect score (MES)
Lasso di tempo: baseline, 6 months
|
Medication effect score for antihyperglycemic medications |
baseline, 6 months
|
|
Participant experience
Lasso di tempo: 6 months
|
Qualitative semi-structured interviews |
6 months
|
|
Physical activity
Lasso di tempo: baseline, 3 months, 6 months
|
Self-reported questionnaire (International Physical Activity Questionnaire (IPAQ) - Long Form) |
baseline, 3 months, 6 months
|
|
Sleep quality and quantity
Lasso di tempo: baseline, 3 months, 6 months
|
Self-reported questionnaire (Pittsburgh Sleep Quality Index (PSQI)) |
baseline, 3 months, 6 months
|
|
Eating behaviours
Lasso di tempo: baseline, 3 months, 6 months
|
Self-reported questionnaire (Eating Disorders Examination Questionnaire (EDEQ)) |
baseline, 3 months, 6 months
|
|
Health literacy
Lasso di tempo: baseline, 3 months, 6 months
|
self-reported questionnaire (Health Literacy Questionnaire (HLQ)) |
baseline, 3 months, 6 months
|
|
Dietary quality
Lasso di tempo: baseline, 3 months, 6 months
|
Assessed using the Healthy Eating Index For Australian adults (HEIFA) |
baseline, 3 months, 6 months
|
|
Diabetes self-management
Lasso di tempo: baseline, 3 months, 6 months
|
Self-reported questionnaire (Diabetes Self-Management Questionnaire (DSMQ-R)) |
baseline, 3 months, 6 months
|
|
Diabetes distress
Lasso di tempo: baseline, 3 months, 6 months
|
Self-reported questionnaire (Type 2 Diabetes Distress Assessment Scale (T2DDAS)) |
baseline, 3 months, 6 months
|
|
Overall well-being
Lasso di tempo: baseline, 3 months, 6 months
|
Self-reported questionnaire (WHO-5) |
baseline, 3 months, 6 months
|
|
Diabetes-specific well-being
Lasso di tempo: baseline, 3 months, 6 months
|
Self-reported questionnaire (DAWN Impact of Diabetes Profile (DIDP-7)) |
baseline, 3 months, 6 months
|
|
Treatment satisfaction
Lasso di tempo: baseline, 3 months, 6 months
|
self-reported questionnaire (Diabetes Treatment Satisfaction Questionnaire (DTSQs (status) and DTSQc (change))) |
baseline, 3 months, 6 months
|
Collaboratori e investigatori
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Completamento primario (Stimato)
Completamento dello studio (Stimato)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
- Malattie del sistema endocrino
- Malattie metaboliche
- Disturbi del metabolismo del glucosio
- Diabete mellito
- Malattie nutrizionali e metaboliche
- Diabete mellito, tipo 2
- Tecniche investigative
- Tecniche di laboratorio clinico
- Tecniche e procedure diagnostiche
- Diagnosi
- Analisi chimica del sangue
- Test di chimica clinica
- Tecniche diagnostiche, endocrino
- Monitoraggio, fisiologico
- Monitoraggio continuo del glucosio
Altri numeri di identificazione dello studio
- 2024-3690HC
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Descrizione del piano IPD
The data that support the findings of this study will be available from the corresponding author for a period of 36 months from publication, upon reasonable request for academic use. The data will not be made publicly available, as it contains information that could compromise research participant consent.
Criteri di accesso alla condivisione IPD
Reasonable requests of data for academic use will be considered. Requests can be made to the corresponding author of the publication. Data will not be made publicly available as it contains information that could compromise research participant consent.
Tipo di informazioni di supporto alla condivisione IPD
- STUDIO_PROTOCOLLO
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
prodotto fabbricato ed esportato dagli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .